{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-146093","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.492268+00:00","generated_at":"2026-06-01T09:20:06.613941+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensei Biotherapeutics reports Phase 1 data for SNS-101: 59% tumor reduction in MSS endometrial cancer, well tolerated","bullets":["Confirmed partial response (59% decrease) in an MSS endometrial cancer patient on SNS-101 plus cemiplimab; remains on study at 30+ weeks.","No dose-limiting toxicities; most AEs grade 1-2; mild cytokine release syndrome at highest dose manageable.","PK profile shows linear elimination and dose-proportional exposure, supporting once-every-3-week dosing.","Tumor regression observed in MSS CRC (27%), pembrolizumab-resistant RCC (18%), and HPV+ head & neck cancer (17%).","Company expects initial dose expansion data and end-of-Phase 1 FDA meeting by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-146093","json":"https://secwatch.observer/filing/0001193125-24-146093.json","markdown":"https://secwatch.observer/filing/0001193125-24-146093.md","text":"https://secwatch.observer/filing/0001193125-24-146093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524146093/0001193125-24-146093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524146093/d830013d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:20:06.613941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}